Skip to content

Preoperative Imaging in DIEP Flap Breast Reconstruction

Preoperative Imagining in DIEP Flap Breast Reconstruction: A Randomized Controlled Trial Evaluating Cost and Patient-Reported Outcomes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02111239
Enrollment
60
Registered
2014-04-11
Start date
2011-06-30
Completion date
2017-11-30
Last updated
2016-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

DIEP, DIEP flap, Breast reconstruction, Breast Cancer, CTA, MRA

Brief summary

The purpose of this study is to determine whether preoperative abdominal imaging using either CT angiogram (CTA), or MR angiogram (MRA) will impact perforator dissection time, cost, and patient outcomes in DIEP flap breast reconstruction.

Detailed description

This study will prospectively compare the clinical, economic and patient outcomes of preoperative imaging using either CTA or MRA with those of no preoperative imaging in patients undergoing deep inferior epigastric perforator (DIEP) flap breast reconstruction. Subjects will randomly undergo either a CTA scan or an MRA scan, or no scan (control) preoperatively. An operative plan based on perforator size and course will be devised by an interventional radiologist and a plastic surgeon. The DIEP flap procedure will be planned for controls. Subjects will not be told if the operative plan is changed intraoperatively. Flap dissection time and changes in operative plan will be recorded intraoperatively and surgeon stress will be evaluated following surgery. Pain and narcotic use will be evaluated preoperatively and on days 1-4 postoperatively. The Breast-Q will be completed preoperatively and at 3 weeks, 3 months and 12 months postoperatively. Groups will be compared in terms of all variables measured.

Interventions

DEVICECTA

pelvic/abdominal CTA scan

DEVICEMRA

pelvic/abdominal MRA scan

Sponsors

Canadian Breast Cancer Foundation
CollaboratorOTHER
Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* candidate for DIEP flap breast reconstruction * speak/read/write English * have undergone or will undergo unilateral or bilateral mastectomy

Exclusion criteria

* previous abdominal surgery that may preclude a DIEP flap reconstruction * active smoker * BMI over 35 * severe claustrophobia * sensitivity to intravenous CT contrast medium (Visipaque 320) or MR contrast medium (Gadovist 1.0) * urgency of surgery that precludes study enrollment

Design outcomes

Primary

MeasureTime frameDescription
Time for flap dissection1 day - during surgeryTime to reach exposure of perforators combined with time for flap elevation will be recorded during the surgical procedure.
Change in BREAST-Q ScoresPreoperatively, Postoperatively at 3 weeks, 3 months, 12 monthsSelf-administered quality of life and outcomes questionnaire for women that undergo breast reconstruction.

Secondary

MeasureTime frameDescription
NASA-Task Load Index (TLX)once - immediately postoperativelyCompleted by the operating surgeon to evaluate workload based on 6 scales: mental demand, physical demand, temporal demand, performance, effort and frustration.
Economic Outcome1 yearThe costs of medical imaging and operating expenses will be calculated and compared between study groups.
Whether change in operative procedure occurred during surgery1 dayChange of operative plan either prior to surgery as a result of preoperative imaging, or intra-operatively, will be recorded
Change in Memorial Pain Assessment Card (MPAC) ScoresBaseline, postoperatively on the first 4 days, and at 3 weeks, 3 months and 12 monthsSelf-administered questionnaire consisting of 4 questions related to pain, pain relief, and mood.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026